Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CagriSema in Type 2 Diabetes
NCT07357740Phase 2Withdrawn
- Sponsor
- Novo Nordisk
- Start
- Aug 2026
- Primary completion
- Aug 2027
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 8
01
Overview
A Phase 2 trial of CagriSema in type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Planned start Aug 2026; status: withdrawn.
02
Drugs
CagriSema
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07357740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07357740.